What is XCellR8?
Based in the United Kingdom, XCellR8 stands as a market leader in the development of non-animal testing protocols. The company provides a comprehensive suite of services, including safety and claims testing, which are essential for brands navigating the complex landscape of regulatory compliance and consumer demand for vegan-certified products. With nearly two decades of operational expertise, XCellR8 serves a diverse client base ranging from agile start-ups to multinational corporations like Unilever. Their proprietary testing methods are not only scientifically robust but also align with the global shift toward sustainable and ethical research practices, effectively bridging the gap between traditional toxicology and modern, humane innovation.
How much funding has XCellR8 raised?
XCellR8 has raised a total of $140K across 1 funding round:
Unspecified
$140K
Unspecified (2021): $140K with participation from Unilever and AstraZeneca
Key Investors in XCellR8
Unilever
A global leader in consumer goods, Unilever focuses on sustainable business practices and invests in innovative technologies that align with their commitment to ethical product development.
AstraZeneca
AstraZeneca PLC is a global, science-led biopharmaceutical company focused on the discovery, development and commercialisation of prescription medicines across multiple therapeutic areas.
What's next for XCellR8?
With this late-stage capital infusion, XCellR8 is poised to accelerate its strategic expansion into broader international markets. The focus will likely shift toward enhancing high-throughput testing capabilities and deepening partnerships within the biopharmaceutical and consumer goods sectors. As regulatory frameworks continue to evolve in favor of non-animal alternatives, XCellR8 is well-positioned to capitalize on the increasing mandate for ethical data. Future growth will be driven by the continued refinement of their bespoke testing solutions, ensuring that they remain at the forefront of the global movement to replace animal-based research with human-relevant, data-driven alternatives.
See full XCellR8 company page
